Dr. Rakesh K. Srivastava
Dr. Rakesh K. Srivastava is an accomplished entrepreneur and is the CEO and President of GLAX Health LLC.
WILMINGTON, DELAWARE, UNITED STATES, August 30, 2022
— Dr. Rakesh K. Srivastava’s Target Therapies for Diabetes, Cancer, and Neurodegenerative Disorders
Cancer is a disease that has taken many lives and brought many families a lot of pain and suffering. Unfortunately, it has no cure, which makes a cancer diagnosis even more devastating. Fortunately, scientists like Dr. Rakesh K. Srivastava have worked round the clock to develop treatments for severe diseases such as cancer, neurodegenerative disorders, and diabetes. Without further ado, let's look into the targeted therapy Dr. Rakesh developed for treating cancer.
Cancer and SABT2
In layman’s terms, a genome is all the genetic information pertaining to a living organism. Each genome in a human being can contain up to 21,000 genes. One of the components of a genome is protein-coding sequences, which account for only 1.5%. On the other hand, gene expression is the process that allows a gene to turn into a cell. Epigenetic regulators and transcription factors control gene expression in the body. One excellent example of a transcription factor is SABT2, an acronym for special AT-rich binding protein-2. SABT2 regulates gene expression by behaving like a transcriptional co-factor and influencing the architecture of the chromatin.
Cancer is a highly complicated condition characterized by the rapid division of abnormal cells that threaten to destroy healthy body cells. Ideally, tumor suppressor genes and oncogenes are responsible for regulating this condition. Dr. Rakesh has recently discovered that SABT2 plays a crucial role in the initiation, metastasis, and progression of cancer. He also observed that SABT2 is highly concentrated in patients with cancer as opposed to healthy individuals who showed low levels of SABT2.
Function of SABT2
According to Dr. Srivastava, SABT2 promotes tumors by enhancing transcription factors such as Sox2, c-Myc, Nanog, and Oct4. SABT2 also controls gene expression necessary for crucial functions such as cell proliferation, DNA replication, pluripotency, cell division, self-renewal of stem cells, and cell cycle. Lastly, SABT2 is responsible for malignant transformation, regulation of stemness, and epithelial-mesenchymal transition.
GLAX Health’s research on the targeted Inhibition of SABT2
Due to its role in regulating stemness, Dr. Rakesh established a link between SABT2 and intratumoral heterogeneity, tumor antigenicity, and immune suppression. He also came up with the brilliant idea of using SABT2 as a biomarker for cancer due to its differential expression. The concentration is also pretty high in cancer patients, making it easy to detect cancer. However, scientists use SABT2 in conjunction with other factors to detect cancer in the body.
With this knowledge, Dr. Rakesh K. Srivastava developed small molecules of SABT2 inhibitors and used nanotechnology to deliver them directly to tumor tissues. Dr. Srivastava strongly believes that using SABT2 inhibitors could boost the positive effects of chemotherapy on patients, increase radio sensitivity and reduce the growth of cancerous cells in the body. These inhibitors could also be effective in preventing cancer before it starts.
Dr. Rakesh K. Srivastava is the CEO and President of GLAX LLC and has worked very hard to develop a drug that could potentially cure cancer. We are pleased to report that GLAX LLC has obtained several patents to use SABT2 as a biomarker and treatment for various cancers.
Contact: Dr. Rakesh Srivastava
www.rksrivastava.com
Email: contact@glaxhealth.com
Rakesh Srivastava
GLAX, LLC.
Comments